The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 116 sources its claims cite were checked for support.
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Open accessAbstract
In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is a FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. This manuscript describes the various fabrication techniques for these devices and the factors affecting their degradation and drug release.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review surveys poly lactic-co-glycolic acid (PLGA) as a biodegradable controlled drug delivery carrier, covering its properties, copolymer systems, fabrication methods, release behavior, degradation factors, toxicology, and modeling. It concludes that PLGA is versatile and FDA-approved, with degradation and release tunable through composition, molecular weight, crystallinity, device geometry, and drug characteristics.
Key findings
- PLGA is biocompatible, biodegradable, FDA-approved, and can be processed into nanospheres, microspheres, and millimeter-sized implants; it degrades by ester hydrolysis into lactic and glycolic acids, which are eliminated through normal metabolic routes or the kidney.
- Degradation rate depends strongly on lactide-to-glycolide ratio: 50:50 PLGA degrades fastest, followed by 65:35, 75:25, and 85:15; higher glycolic acid content increases degradation, while higher molecular weight generally slows it. PLGA copolymers have a glass transition temperature above 37 °C and are glassy at physiological temperature.
- Drug release is often biphasic, with an initial burst followed by slower diffusion and erosion; release is influenced by drug type and load, matrix surface-area-to-volume ratio, pH, crystallinity, and possibly enzymes, though reports on crystallinity and enzymatic degradation conflict.
- Fabrication approaches include single and double emulsion, coacervation, spray drying, nanoprecipitation, salting out, solvent casting and compression molding, extrusion, supercritical CO₂ foaming, and multifunctional micro/nanoparticles; PLGA/PEG block copolymers can form thermogels but may reduce encapsulation efficiency.
Methods
- Narrative review of prior literature; no experimental study, systematic search strategy, or primary data collection is described.
- Synthesizes published work on PLGA physicochemical properties, pharmacokinetics and biodistribution, copolymer architectures, fabrication techniques, drug release behavior, degradation factors, toxicology, and mathematical modeling.
- Includes equations for diffusion-controlled release, first-order molecular weight loss, and particle-size distributions such as Weibull or Rosin–Rammler models.
Limitations
- The paper states that mechanisms of PLGA degradation and release are not clearly understood, that crystallinity effects are conflicting, that the role of enzymes is unresolved, and that in vivo and in vitro degradation rates often do not correlate well.
- It notes that nanoscale PLGA may have distinct biodistribution and toxicological profiles, and that local tissue reactions at application sites can occur, though generally mild.
- Evident from the text: as a narrative review, it lacks systematic search criteria, quality appraisal, and quantitative synthesis, so conclusions rest on selected cited studies rather than a formal evidence assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 of 116 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The main advantage of this approach over micro/nanospheres is related to the ability to manage adverse events, since implants retain a degree of reversibility which is not available in depot mechanisms [12,59].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [12] Siegel, 2006, Effect of drug type on the degradation rate of PLGA matrices, Eur. J. Pharm. Biopharm. source
- Supportedcites [59] Rabin, 2008, In vitro and in vivo demonstration of risperidone implants in mice, Schizophr. Res. source
The Introduction describes depot injections as irreversible and says the implants bypass that limitation. The Discussion (Potential Advantages) says implants can be removed if a problem arises, supporting the claimed advantage for managing adverse events. The paper describes fabrication by solvent casting in Materials and Methods; it does not separately compare the implants with micro- or nanospheres. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, the high rate clearance of micro/nanoparticles by the body’s reticuloendothelial system (RES) and the difficultyfor such particles to penetrate many tissue types may limit their use to the vascular space [69–71].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Not checked — no full text of the sourcecites [69] Xu, 2010, Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging, Biomaterials source
- Could not verifycites [70] Zhang, 2010, Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy, J. Biomed. Opt. sourceExperimental — accuracy not yet measured
The Abstract discusses micro- and nanobubbles for imaging and intraocular drug delivery, but does not address clearance by the reticuloendothelial system or difficulty penetrating tissue. Searches for those mechanisms and for confinement to the vascular space found no relevant passage in our copy. Page numbers were not provided. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [71] Sun, 2008, Multifunctional poly(D,L-lactide-co-glycolide)/ montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer, Biomaterials source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Such multifunctional particles can also be formulated from a component material to reduce side effects of the encapsulated drug [70].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Partly supportedcites [70] Zhang, 2010, Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy, J. Biomed. Opt. sourceExperimental — accuracy not yet measured
The paper describes multifunctional PLGA microbubbles made from a biocompatible, biodegradable material for targeted delivery (Abstract; page unavailable). It does not report reduced drug side effects; the encapsulated substance in this study was Texas Red dye, while the anti-VEGF drug Avastin was conjugated to the microbubble surface. (LLM, conf=0.87)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Biodistribution and pharmacokinetics of PLGA follows a non-linear and dose-dependent profile [14].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [14] Yang, 2001, Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method, Biomaterials source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Better release kinetics from formulations of diblock copolymers have been demonstrated in comparison to PLGA alone.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Using these techniques, processing parameters such as orientation of jets, material flow rates, and rate of solvent extraction can be controlled to create uniform and well-centered double-walled microspheres exhibiting a controllable shell thickness [52].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [52] Berkland, 2004, Uniform double-walled polymer microspheres of controllable shell thickness, J. Control. Release source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“PLGA physical properties themselves have been shown to depend upon multiple factors, including the initial molecular weight, the ratio of lactide to glycolide, the size of the device, exposure to water (surface shape) and storage temperature [11].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [11] Houchin, 2009, Physical properties of PLGA films during polymer degradation, J. Appl. Polym. Sci. source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 22
- It may state two separate claims as one. 27
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Solvent casting is a method to fabricate a macroscopic millimeter size formulation which can be implanted or inserted for long term medication [59].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Partly supportedcites [59] Rabin, 2008, In vitro and in vivo demonstration of risperidone implants in mice, Schizophr. Res. sourceExperimental — accuracy not yet measured
The Materials and Methods (page not given) describe solvent casting risperidone and polymer, then molding or extruding the film into implantable pellets or rods. The Introduction and Conclusions describe long-term drug delivery, but the passages do not specify millimeter-sized dimensions; the demonstrated use is a risperidone implant in mice, not a general formulation for long-term medication. (LLM, conf=0.81)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGA-PEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
What the sources say
- Supportedcites [18] Cheng, 2007, Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery, Biomaterials source
The citation to this paper is attached to the diblock (PLGA-PEG) portion of the sentence, not the triblock types. Sections 2.2.1 and 3.1 describe synthesizing PLGA-b-PEG by conjugating a PLGA block with a PEG block. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [19] Li, 2001, PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats, J. Control. Release source
- Not checked — no full text of the sourcecites [20] Ghahremankhani, 2007, PLGA-PEG-PLGA tri-block copolymers as an in-situ gel forming system for calcitonin delivery, Polym. Bull. source
- Not checked — no full text of the sourcecites [21] Jeong, 2000, In situ gelation of PEGPLGAPEG triblock copolymer aqueous solutions and degradation thereof, J. Biomed. Mater. Res. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Unlike solvent-casting, extrusion is a continuous process of drawing polymer-drug mixture through a die to create implants of fixed cross-sectional profile without any use of solvent.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Supportedcites [61] Wang, 2010, A rapid method for creating drug implants: Translating laboratory-based methods into a scalable manufacturing process, J. Biomed. Mater. Res. Part B Appl. Biomater. source
The Discussion describes extrusion, in contrast to solvent-casting, as a continuous, solvent-free process for making drug implants. Materials and Methods > Extrusion describes feeding a polymer–drug mixture through an extruder die to produce rods, consistent with the claimed fixed cross-sectional profile. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Salting out is another method in which a water-in-oil emulsion is first formed containing polymer, solvent (usually non chlorinated like acetone), salt (e.g., magnesium acetate tetrahydrate) and stabilizer. Water is then added to the solution until the volume is sufficient to diffuse acetone into the water, resulting in nanoparticle formulations [55–58].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [55] Lamprecht, 2000, Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [56] Murakami, 1999, Preparation of poly(D,L-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [57] Konan, 2003, Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy, Eur. J. Pharm. Biopharm. source
- Not checked — no full text of the sourcecites [58] Kwon, 2001, Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method, Colloids Surf. A Physicochem. Eng. Asp. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The main disadvantage of this process is the adhesion of the microparticles to the inner walls of the spray-dryer.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A modification on this procedure called the double or multiple emulsion technique has become the favored protocol for encapsulating hydrophilic compounds and proteins [37].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [37] Mao, 2007, Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres, Int. J. Pharm. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“It is soluble in wide range of common solvents including chlorinated solvents, tetrahydofuran, acetone or ethyl acetate [7,10].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [7] Uhrich, 1999, Polymeric systems for controlled drug release, Chem. Rev. source
- Not checked — no full text of the sourcecites [10] Wu, 2001, Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: Biodegradation, J. Biomater. Sci. Polym. Ed. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Additionally, microfluidic devices can incorporate the use of electrostatic forces to control the size and shape of particles for increased tuning of release characteristics [53].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [53] Loscertales, 2002, Micro/Nano encapsulation via electrified coaxial liquid jets, Science source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Nanoparticles can also be synthesized by nanoprecipitation methods. Polymer and drug are dissolved in acetone and added to an aqueous solution containing Pluronic F68. The acetone is evaporated at appropriate temperatures and reduced pressures leaving behind the polymer encapsulated nanoparticles with drug [54].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [54] Hans, 2002, Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Drug delivery of peptides and proteins may also require parenteral formulations to avoid degradation in the digestive tract and first pass metabolism, while the short circulating half-lives of peptides and proteins contribute to the need for parenteral formulations that will reduce dosing frequency.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Presence of methyl side groups in PLA makes it more hydrophobic than PGA and hence lactide rich PLGA copolymers are less hydrophilic, absorb less water and subsequently degrade more slowly.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alternatively, spray drying is very rapid, convenient and has very few processing parameters, making it suitable for industrial scalable processing.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The copolymer is usually a free flowing solution at low temperature and can form a high viscosity gel at body temperature.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mechanical strength, swelling behavior, capacity to undergo hydrolysis and subsequently biodegradation rate of the polymer are directly influenced by the degree of crystallinity of the PLGA, which is further dependent on the type and molar ratio of the individual monomer components in the copolymer chain.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Emulsion techniques require precise control of processing parameters for higher encapsulation efficiency, and phase separation techniques tend to produce agglomerated particles and also require removal of large quantities of the organic phase from the microspheres. This makes the process difficult for mass production.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Degree of crystallinity and melting point of the polymers are directly related to the molecular weight of the polymer.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Biocompatibility is clearly important, although it is important to note that biocompatibility is not an intrinsic property of a material, but depends on the biological environment and the tolerability that exists with respect to specific drug-polymer-tissue interactions [9].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers
What the sources say
- Not checked — no full text of the sourcecites [9] Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev. source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Recently, coaxial capillary flows have become a preferable technique to produce monodispersed micro/nanoparticles with either simple or core-shell structure because of their precise control on mean particle size [50,51].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [50] Barrero, 2007, Micro- and nanoparticles via capillary flows, Annu. Rev. Fluid Mech. source
- Not checked — no full text of the sourcecites [51] Freitas, 2005, Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology, J. Control. Release source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Drugs formulated in such polymeric devices are released either by diffusion through the polymer barrier, or by erosion of the polymer material, or by a combination of both diffusion and erosion mechanisms.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As a rule, higher content of PGA leads to quicker rates of degradation with an exception of 50:50 ratio of PLA/PGA, which exhibits the fastest degradation, with higher PGA content leading to increased degradation interval below 50%.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The degradation of the PLGA carriers is quick on the initial stage (around 30%) and slows eventually to be cleared by respiration in the lung [16].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [16] Bazile, 1992, Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats, Biomaterials source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This method is known to encapsulate all kinds of drugs/peptides/proteins into microparticles without significant loss in their biological activity.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Crystalline PGA, when co-polymerized with PLA, reduces the degree of crystallinity of PLGA and as a result increase the rate of hydration and hydrolysis.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Triblock copolymers of both ABA and BAB type can act as a thermogel with an A-block covalently coupled with a B-block via ester link.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Tg (glass transition temperature) of the PLGA copolymers are reported to be above the physiological temperature of 37 °C and hence are glassy in nature, thus exhibiting fairly rigid chain structure.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The nature of solvent used, temperature of the solvent evaporation and feed rate affects the morphology of the microspheres.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Water-in-oil-in-water emulsion methods are best suited to encapsulate water-soluble drugs like peptides, proteins, and vaccines, unlike single emulsion methods which is ideal for water-insoluble drugs like steroids.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“This layer of PEG acts as a barrier and reduces the interactions with foreign molecules by steric and hydrated repulsion, giving enhanced shelf stability [22].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
What the sources say
- Not checked — no full text of the sourcecites [22] Tobio, 1998, Stealth PLA-PEG nanoparticles as protein carriers for nasal administration, Pharm. Res. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The role of enzymes in any PLGA biodegradation is unclear. Most literature indicate that the PLGA biodegradation does not involve any enzymatic activity and is purely through hydrolysis. However, some investigators have suggested an enzymatic role in PLGA breakdown based upon the difference in the in vitro and in vivo degradation rates.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.1. Biphasic Release
What the sources say
- Not checked — no full text of the sourcecites [80] Alexis, 2005, Factors affecting the degradation and drug-release mechanism of poly (lactic acid) and poly [(lactic acid)-co-(glycolic acid)], Polym. Int. source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Denatured species are therapeutically inactive and can cause unpredictable side effects, such as immunogenicity or other toxicity.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [60] Widmer, 1998, Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration, Biomaterials source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“At the moment, there are conflicting reports on the effect of crystallinity on the degradation rate [80].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [80] Alexis, 2005, Factors affecting the degradation and drug-release mechanism of poly (lactic acid) and poly [(lactic acid)-co-(glycolic acid)], Polym. Int. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The PLGA polymer biodegrades into lactic and glycolic acids. Lactic acid enters the tricarboxylic acid cycle and is metabolized and subsequently eliminated from the body as carbon dioxide and water [75]. Glycolic acid is either excreted unchanged in the kidney or it enters the tricarboxylic acid cycle and is eventually eliminated as carbon dioxide and water.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.1. Biphasic Release
What the sources say
- Not checked — no full text of the sourcecites [75] Crotts, 1998, Protein delivery from poly (lactic-co-glycolic acid) biodegradable microspheres: Release kinetics and stability issues, J. Microencapsul. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“After such pressurization and rapid depressurization sequence, the thermodynamic instability of CO2 molecules leads to their clustering inside the liquid polymer. As CO2 leaves, the emulsion results in a porous polymer structure [66,67].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Not checked — no full text of the sourcecites [66] Koushik, 2004, Preparation of large porous Deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process, Pharm. Res. source
- Not checked — no full text of the sourcecites [67] Davies, 2008, Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering, Adv. Drug Deliv. Rev. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“PLGA 50:50 (PLA/PGA) exhibited a faster degradation than PLGA 65:35 due to preferential degradation of glycolic acid proportion assigned by higher hydrophilicity. Subsequently PLGA 65:35 shows faster degradation than PLGA 75:25 and PLGA 75:25 than PLGA 85:15 [79].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [79] Park, 1995, Degradation of poly(lactic-co-glycolic acid) microspheres: Effect of copolymer composition, Biomaterials source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Third, solvent-casting and compression molding are not continuous processes, which may increase batch-to-batch variation in the composition of implants as well as cost of manufacturing [60].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [60] Widmer, 1998, Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration, Biomaterials source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The ratio of surface area to volume has shown to be a significant factor for degradation of large devices. Higher surface area ratio leads to higher degradation of the matrix.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [82] Schliecker, 2003, Hydrolytic degradation of poly(lactide-co-glycolide) films: Effect of oligomers on degradation rate and crystallinity, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [86] Witt, 2001, Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: Is the erosion controlled by degradation, swelling or diffusion?, Eur. J. Pharm. Biopharm. source
- Not checked — no full text of the sourcecites [87] Grizzi, 1995, Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence, Biomaterials source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 5. Conclusions and Future Prospects
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
In the paper
“The first stage of drug release is through random scission of the polymer without any polymer weight loss and is mainly through diffusion, while the second stage is characterized by the onset of weight loss.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.4. Modeling of PLGA Drug Release Profiles
What the sources say
- Not checked — no full text of the sourcecites [96] Berchane, 2007, Effect of mean diameter and polydispersity of PLG microspheres on drug release: Experiment and theory, Int. J. Pharm. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Several studies suggest that nanoparticles of any material may create specific biodistribution and toxicological profiles [95].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.3. Toxicology
What the sources say
- Not checked — no full text of the sourcecites [95] Olivier, 1999, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm. Res. source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, multiple studies demonstrate that PLGA can easily be formulated into the drug carrying devices at all scales, i.e., as nanospheres, as microspheres and even as millimeter sized implants, can encapsulate a wide range of drugs, peptides or proteins and can be delivered over different periods of time with diverse routes of delivery.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 5. Conclusions and Future Prospects
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
A pulsated drug release profile is sometimes preferred over continuous drug presence because continuous presence may lead to receptor downregulation or tolerance development.
“A pulsated drug release profile is sometimes preferred over the continuous presence of the drug, which may lead to downregulation of receptors or the development of tolerance.”
The paper relies on this without support.
Large macroscopic formulations act as a drug reservoir that can be delivered over a longer interval.
“Large size, macroscopic formulations act as a reservoir for drug that can be delivered over a longer interval.”
The paper relies on this without support.
All microparticle preparation techniques described earlier can be employed for manufacturing PLGA nanoparticles by adjusting processing parameters.
“All the above described microparticle techniques can be employed for manufacturing PLGA nanoparticles (nanospheres and nanocapsules) by adjusting the processing parameters.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It allows for adjustable degradation rates and hydrophilicity by changing the PGA:PLA ratio, where higher PLA concentrations increase hydrophobicity, degradation time, and consequently incorporated drug release.[ 201 ]”
From Unraveling and Harnessing the Immune Response at the Cell–Biomaterial Interface for Tissue Engineering Purposes (2024) · cites this paper as [201]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Examples of polyesters for solubilizing hydrophobic drugs are PCL, PDLLA and PLGA [106–108].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [106]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and the material mineralization can be expedited in the presence of immobilized growth factors [91–95].”
From Polydopamine-Assisted Surface Modification for Bone Biosubstitutes (2016) · cites this paper as [91]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Upon immobilization of BMP, the property of osteoblast cells responsive to polymeric materials can be remarkably improved”
From Polydopamine-Assisted Surface Modification for Bone Biosubstitutes (2016) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Drug release occurs via bulk degradation of the polymer and drug diffusion 12 and can be modified by altering the hydrophobicity of the monomer, polymer chain length and particle size 13 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Opposite device-size trends for degradation
MajorThe conclusion says a larger volume-to-surface ratio accelerates degradation, while Section 4.2.5 says a higher surface-area-to-volume ratio increases degradation. These ratios move in opposite directions.
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
“The ratio of surface area to volume has shown to be a significant factor for degradation of large devices. Higher surface area ratio leads to higher degradation of the matrix.”
PDLA and PLLA are described as physically alike and structurally unlike
MinorThe paper calls their physicochemical properties nearly the same, then describes PLLA as highly crystalline and PDLA as completely amorphous. Those are substantially different physical properties.
“The physicochemical properties of optically active PDLA and PLLA are nearly the same.”
“In general, the polymer PLA can be made in highly crystalline form (PLLA) or completely amorphous (PDLA) due to disordered polymer chains.”
Opposite device-size ratios are said to accelerate degradation
MinorThe discussion says a higher surface-area-to-volume ratio increases degradation, while the conclusion says a larger volume-to-surface ratio accelerates it. Those ratios move in opposite directions.
“Higher surface area ratio leads to higher degradation of the matrix.”
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
The model reverses its boundary and initial-condition labels
MinorEquation (3), called an initial condition, instead specifies concentration at the particle surface for times greater than zero. Equation (2), called a boundary condition, is restricted to time zero.
“The above equation is solved using the following boundary conditions of concentration profile (2) and initial condition (3).”
“(2)∂C(r,t)∂r|r=0,t=0=0 (3)C(r,t)|r=R,t>0=0 where R is the radius of the particle (if spherical).”
Citations
Cites
Biodegradable polymers as biomaterials
Nair, L. S., & Laurencin, C. T. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.017 · Cited by 4,416 · cited 1×
“The basic category of biomaterials used in drug delivery can be broadly classified as (1) synthetic biodegradable polymers, which includes relatively hydrophobic materials such as the α-hydroxy acids (a family that includes poly lactic-coglycolic acid, PLGA), polyanhydrides, and others, and (2) naturally occurring pol…”
BackgroundPolymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“It is soluble in wide range of common solvents including chlorinated solvents, tetrahydofuran, acetone or ethyl acetate [7,10].”
BackgroundBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · cited 2×
“This section describes various fabrication techniques of PLGA controlled drug delivery devices [9].”
BackgroundMethodJain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273 · cited 5×
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGAPEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
BackgroundInfluentialMundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., & Aminabhavi, T. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.013 · Cited by 1,025 · cited 1×
“Additionally, it is possible to tune the overall physical properties of the polymer-drug matrix by controlling the relevant parameters such as polymer molecular weight, ratio of lactide to glycolide and drug concentration to achieve a desired dosage and release interval depending upon the drug type [4–6].”
BackgroundMicro/Nano encapsulation via electrified coaxial liquid jets
Loscertales, I. G., Barrero, A., Guerrero, I., Cortijo, R., Marquez, M., & Gañán-Calvo, A. M. (2002) · Science · doi:10.1126/science.1067595 · Cited by 1,017 · cited 1×
“Additionally, microfluidic devices can incorporate the use of electrostatic forces to control the size and shape of particles for increased tuning of release characteristics [53].”
Dhar, S., Gu, F., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994 · cited 1×
“Various mechanisms of targeted delivery of drugs from diblock nanoparticles have also been reported [18,23,24].”
BackgroundFreitas, S., Merkle, H. P., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.015 · Cited by 923 · cited 1×
“Recently, coaxial capillary flows have become a preferable technique to produce monodispersed micro/nanoparticles with either simple or core-shell structure because of their precise control on mean particle size [50,51].”
MethodHydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence
Grizzi, I., Garreau, H., Li, S., & Vert, M. (1995) · Biomaterials · doi:10.1016/0142-9612(95)93258-f · Cited by 895 · cited 1×
“It has also been reported that bulk degradation is faster than pure surface degradation for PLGA, which makes the release of the drug faster from the devices with higher surface area to volume [82,86,87].”
BackgroundMathematical modeling of bioerodible, polymeric drug delivery systems
Siepmann, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00116-8 · Cited by 791 · cited 1×
“where Mw(t = 0) is the molecular weight of the polymer at time t = 0 and kdeg is the polymer degradation constant [74,97,98].”
BackgroundYang, Y. (2001) · Biomaterials · doi:10.1016/s0142-9612(00)00178-2 · Cited by 720 · cited 1×
“Biodistribution and pharmacokinetics of PLGA follows a non-linear and dose-dependent profile [14].”
BackgroundIn vitro and in vivo degradation of porous poly(dl-lactic-co-glycolic acid) foams
Lu, L., Peter, S. J., D. Lyman, M., Lai, H.-L., Leite, S. M., Tamada, J. A., Uyama, S., Vacanti, J. P., Langer, R., & Mikos, A. G. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00047-8 · Cited by 668 · cited 1×
“A systematic study of polymer composition with its degradation has been shown by many groups [77,78].”
BackgroundDegradation of poly(lactic-co-glycolic acid) microspheres: Effect of copolymer composition
Park, T. G. (1995) · Biomaterials · doi:10.1016/0142-9612(95)93575-x · Cited by 642 · cited 1×
“Subsequently PLGA 65:35 shows faster degradation than PLGA 75:25 and PLGA 75:25 than PLGA 85:15 [79].”
BackgroundFolate receptor targeted biodegradable polymeric doxorubicin micelles
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.003 · Cited by 620 · cited 1×
“Various mechanisms of targeted delivery of drugs from diblock nanoparticles have also been reported [18,23,24].”
BackgroundPaclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation
Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand‐Brynaert, J., Féron, O., & Véronique Préat, A. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.086 · Cited by 617 · cited 1×
“Therefore, the remaining gel becomes more hydrophobic in an aqueous environment, resulting in less water content [20,25–28].”
BackgroundEffect of acidic pH on PLGA microsphere degradation and release
Zolnik, B. S., & Burgess, D. J. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.034 · Cited by 560 · cited 1×
“difference between the slightly acidic and neutral media is less pronounced due to autocatalysis by the carboxylic end groups [89].”
BackgroundPEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats
Li, Y.-P., Pei, Y.-Y., Zhang, X.-Y., Gu, Z.-H., Zhou, Z.-H., Yuan, W.-F., Zhou, J.-J., Zhu, J.-H., & Gao, X.-J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00218-8 · Cited by 540 · cited 4×
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGAPEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
BackgroundInfluentialMulti-pulse drug delivery from a resorbable polymeric microchip device
Grayson, A. C. R., Choi, I. S., Tyler, B. M., Wang, P. P., Brem, H., Cima, M. J., & Langer, R. (2003) · Nature Materials · doi:10.1038/nmat998 · Cited by 444 · cited 1×
“For example, a single biodegradable polymeric microchip can be constructed of PLGA and/or PLLA in combination with multiple drugs to achieve pulsatile drug delivery over a long period of time [65].”
BackgroundAlexis, F. (2005) · Polymer International · doi:10.1002/pi.1697 · Cited by 443 · cited 2×
“At the moment, there are conflicting reports on the effect of crystallinity on the degradation rate [80].”
BackgroundBiocompatibility analysis of poly(glycerol sebacate) as a nerve guide material
Sundback, C. A., Shyu, J. Y., Wang, Y., Faquin, W. C., Langer, R. S., Vacanti, J. P., & Hadlock, T. A. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.02.004 · Cited by 443 · cited 1×
“Toxicological studies with PLGA devices suggest that local tissue reactions at the site of application may occur [93,94].”
BackgroundMurakami, H., Kobayashi, M., Takeuchi, H., & Kawashima, Y. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00187-8 · Cited by 405
Stealth PLA-PEG nanoparticles as protein carriers for nasal administration
Tobío, M., Gref, R., Sánchez, A., Langer, R., & Alonso, M. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011922819926 · Cited by 402 · cited 1×
“This layer of PEG acts as a barrier and reduces the interactions with foreign molecules by steric and hydrated repulsion, giving enhanced shelf stability [22].”
BackgroundWidmer, M. S., Gupta, P. K., Lu, L., Meszlenyi, R. K., Evans, G. R. D., Brandt, K., Savel, T., Gurlek, A., Patrick, C. W., & Mikos, A. G. (1998) · Biomaterials · doi:10.1016/s0142-9612(98)00099-4 · Cited by 372 · cited 1×
“Third, solvent-casting and compression molding are not continuous processes, which may increase batch-to-batch variation in the composition of implants as well as cost of manufacturing [60].”
BackgroundMicroparticle formation and its mechanism in single and double emulsion solvent evaporation
Rosca, I. D., Watari, F., & Uo, M. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.007 · Cited by 365 · cited 1×
“The resultant solid microspheres are then washed and dried under appropriate conditions to give a final injectable microsphere formulation [32–35].”
BackgroundDegradation of poly (D,L-lactic acid) microspheres: Effect of molecular weight
Park, T. G. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90263-1 · Cited by 359 · cited 2×
“Effect of Weight Average Molecular Weight (Mw)—Polymers with higher molecular weight have generally exhibited lower degradation rates [83].”
BackgroundFaisant, N., Siepmann, J., & Benoit, J. P. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00023-4 · Cited by 346 · cited 1×
“where Mw(t = 0) is the molecular weight of the polymer at time t = 0 and kdeg is the polymer degradation constant [74,97,98].”
BackgroundPEGylated PLGA-based nanoparticles targeting M cells for oral vaccination
Garinot, M., Fiévez, V., Pourcelle, V., Stoffelbach, F., des Rieux, A., Plapied, L., Theate, I., Freichels, H., Jérôme, C., Marchand-Brynaert, J., et al. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.021 · Cited by 331 · cited 1×
“Therefore, the remaining gel becomes more hydrophobic in an aqueous environment, resulting in less water content [20,25–28].”
BackgroundWu, X. S., & Wang, N. (2001) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856201744425 · Cited by 317 · cited 1×
“It is soluble in wide range of common solvents including chlorinated solvents, tetrahydofuran, acetone or ethyl acetate [7,10].”
Mohamed, F., & van der Walle, C. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21082 · Cited by 299 · cited 1×
“Additionally, it is possible to tune the overall physical properties of the polymer-drug matrix by controlling the relevant parameters such as polymer molecular weight, ratio of lactide to glycolide and drug concentration to achieve a desired dosage and release interval depending upon the drug type [4–6].”
BackgroundDavies, O. R., Lewis, A. L., Whitaker, M. J., Tai, H., Shakesheff, K. M., & Howdle, S. M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.12.001 · Cited by 299 · cited 1×
“As CO2 leaves, the emulsion results in a porous polymer structure [66,67].”
BackgroundLi, M., & Feng, S. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00440-0 · Cited by 288
Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method
Kwon, H.-Y., Lee, J.-Y., Choi, S.-W., Jang, Y., & Kim, J.-H. (2001) · Colloids and Surfaces A: Physicochemical and Engineering Aspects · doi:10.1016/s0927-7757(00)00825-6 · Cited by 286
MAO, S., XU, J., CAI, C., GERMERSHAUS, O., SCHAPER, A., & KISSEL, T. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.036 · Cited by 283 · cited 2×
“In double emulsion processes, choice of solvents and stirring rate predominantly affects the encapsulation efficiency and final particle size [32,36,37].”
BackgroundMethodChemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms
Houchin, M. L., & Topp, E. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21176 · Cited by 277 · cited 1×
“Maintaining adequate shelf-life of peptide and protein drugs often requires solid-state formulation to limit hydrolytic degradation reactions [31].”
BackgroundSun, B., Ranganathan, B., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.09.038 · Cited by 274 · cited 1×
“However, the high rate clearance of micro/nanoparticles by the body’s reticuloendothelial system (RES) and the difficultyfor such particles to penetrate many tissue types may limit their use to the vascular space [69–71].”
BackgroundCrotts, G., & Park, T. G. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809008253 · Cited by 263 · cited 1×
“Lactic acid enters the tricarboxylic acid cycle and is metabolized and subsequently eliminated from the body as carbon dioxide and water [75].”
BackgroundPreparation of biodegradable microspheres and microcapsules: 2. Polyactides and related polyesters
Arshady, R. (1991) · Journal of Controlled Release · doi:10.1016/0168-3659(91)90126-x · Cited by 258 · cited 1×
“In double emulsion processes, choice of solvents and stirring rate predominantly affects the encapsulation efficiency and final particle size [32,36,37].”
BackgroundIn vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam
Holy, C. E., Dang, S. M., Davies, J. E., & Shoichet, M. S. (1999) · Biomaterials · doi:10.1016/s0142-9612(98)00256-7 · Cited by 241 · cited 1×
“The in vitro biodegradation/hydrolysis of PLGA showed that both alkaline and strongly acidic media accelerate polymer degradation [88].”
BackgroundPhase inversion dynamics of PLGA solutions related to drug delivery
Graham, P. D., Brodbeck, K. J., & McHugh, A. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00158-8 · Cited by 222 · cited 1×
“The processing parameters including polymer concentration, quenching temperature, quenching time and solvent composition affect the morphology and size of the microspheres [41–43].”
BackgroundDailey, L. A., Jekel, N., Fink, L., Gessler, T., Schmehl, T., Wittmar, M., Kissel, T., & Seeger, W. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.01.016 · Cited by 220 · cited 1×
“Toxicological studies with PLGA devices suggest that local tissue reactions at the site of application may occur [93,94].”
BackgroundMicro- and nanoparticles via capillary flows
Barrero, A., & Loscertales, I. G. (2007) · Annual Review of Fluid Mechanics · doi:10.1146/annurev.fluid.39.050905.110245 · Cited by 219 · cited 1×
“Recently, coaxial capillary flows have become a preferable technique to produce monodispersed micro/nanoparticles with either simple or core-shell structure because of their precise control on mean particle size [50,51].”
MethodEffect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles
Panagi, Z., Beletsi, A., Evangelatos, G., Livaniou, E., Ithakissios, D. S., & Avgoustakis, K. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00676-7 · Cited by 215 · cited 1×
“Furthermore, previous studies suggest that both blood clearance and uptake by the mononuclear phagocyte system (MPS) may depend on dose and composition of PLGA carrier systems [15].”
BackgroundOlivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213 · cited 1×
“Several studies suggest that nanoparticles of any material may create specific biodistribution and toxicological profiles [95].”
BackgroundHile, D. D., Amirpour, M. L., Akgerman, A., & Pishko, M. V. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00268-0 · Cited by 210 · cited 1×
“Since micro-porous foams have higher surface-to-volume ratios, more efficient drug release has been reported [68].”
BackgroundEffect of drug type on the degradation rate of PLGA matrices
SIEGEL, S., KAHN, J., METZGER, K., WINEY, K., WERNER, K., & DAN, N. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.06.009 · Cited by 208 · cited 3×
“The main advantage of this approach over micro/nanospheres is related to the ability to manage adverse events, since implants retain a degree of reversibility which is not available in depot mechanisms [12,59].”
BackgroundSelf-citationControlled release from bioerodible polymers: Effect of drug type and polymer composition
Frank, A., Rath, S. K., & Venkatraman, S. S. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.019 · Cited by 201 · cited 1×
“parameters of drug release rate vary as a function of drug type [85].”
BackgroundBazile, D. V., Ropert, C., Huve, P., Verrecchia, T., Mariard, M., Frydman, A., Veillard, M., & Spenlehauer, G. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90142-b · Cited by 200 · cited 1×
“The degradation of the PLGA carriers is quick on the initial stage (around 30%) and slows eventually to be cleared by respiration in the lung [16].”
BackgroundIn vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants
Ramchandani, M., & Robinson, D. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00113-2 · Cited by 195 · cited 1×
“This has been demonstrated in both in vivo and in vitro for various drug types and proteins with different polymer ratios [72,73].”
BackgroundRUHE, Q. P., HEDBERG, E. L., PADRON, N. T., SPAUWEN, P. H. M., JANSEN, J. A., & MIKOS, A. G. (2003) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200300003-00013 · Cited by 186 · cited 1×
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
BackgroundLamprecht, A., Ubrich, N., Hombreiro Pérez, M., Lehr, C.-M., Hoffman, M., & Maincent, P. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00422-6 · Cited by 185 · cited 1×
“Water is then added to the solution until the volume is sufficient to diffuse acetone into the water, resulting in nanoparticle formulations [55–58].”
BackgroundSah, H. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)01647-7 · Cited by 179 · cited 1×
“The resultant solid microspheres are then washed and dried under appropriate conditions to give a final injectable microsphere formulation [32–35].”
BackgroundRaman, C., Berkland, C., Kim, K. (., & Pack, D. W. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.11.012 · Cited by 166 · cited 2×
“where M1 is the total mass of the drug in the population, Mdrug is the mass of drug in one particle and r is the radius of the particle [97].”
BackgroundPasserini, N., & Craig, D. Q. M. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00245-0 · Cited by 165 · cited 1×
“It has been further reported that Tg of PLGAs decrease with a decrease of lactide content in the copolymer composition and with a decrease in molecular weight [13].”
BackgroundHua, F. J., Kim, G. E., Lee, J. D., Son, Y. K., & Lee, D. S. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.10121 · Cited by 163 · cited 1×
“The processing parameters including polymer concentration, quenching temperature, quenching time and solvent composition affect the morphology and size of the microspheres [41–43].”
BackgroundEnzymatic degradation behavior and mechanism of Poly(lactide-co-glycolide) foams by trypsin
Cai, Q. (2002) · Biomaterials · doi:10.1016/s0142-9612(02)00377-0 · Cited by 161 · cited 1×
“Due to a lack of uniformity in in vivo tests, there is difficulty in comparing and demonstrating the choice of proposed enzymes and their contribution in the degradation process [90,91].”
BackgroundGavini, E., Chetoni, P., Cossu, M., et al. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2003.10.018 · Cited by 160 · cited 1×
“Various spray drying techniques have been reported [44–49].”
MethodEsmaeili, F., Ghahremani, M. H., Esmaeili, B., Khoshayand, M. R., Atyabi, F., & Dinarvand, R. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.07.038 · Cited by 159 · cited 1×
“To address these limitations, studies have investigated the role of surface modification, suggesting that incorporation of surface modifying agents can significantly increase blood circulation half-life [17].”
BackgroundKonan, Y. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00128-5 · Cited by 152 · cited 1×
“Water is then added to the solution until the volume is sufficient to diffuse acetone into the water, resulting in nanoparticle formulations [55–58].”
BackgroundSchliecker, G., Schmidt, C., Fuchs, S., Wombacher, R., & Kissel, T. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00379-x · Cited by 146 · cited 2×
“In contrast, various other studies have shown a decrease of degradation rate with increase in sample crystallinity [82].”
BackgroundResultBouissou, C., Rouse, J. J., Price, R., & van der Walle, C. F. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0180-2 · Cited by 145 · cited 1×
“of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
BackgroundEnzymatic degradation of polylactide stereocopolymers with predominant d-lactyl contents
Li, S., Girard, A., Garreau, H., & Vert, M. (2000) · Polymer Degradation and Stability · doi:10.1016/s0141-3910(00)00152-x · Cited by 143 · cited 1×
“Due to a lack of uniformity in in vivo tests, there is difficulty in comparing and demonstrating the choice of proposed enzymes and their contribution in the degradation process [90,91].”
BackgroundPhysical properties of PLGA films during polymer degradation
Houchin, M. L., & Topp, E. M. (2009) · Journal of Applied Polymer Science · doi:10.1002/app.30813 · Cited by 133 · cited 1×
“PLGA physical properties themselves have been shown to depend upon multiple factors, including the initial molecular weight, the ratio of lactide to glycolide, the size of the device, exposure to water (surface shape) and storage temperature [11].”
BackgroundUniform double-walled polymer microspheres of controllable shell thickness
Berkland, C., Pollauf, E., Pack, D. W., & Kim, K. (. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.018 · Cited by 131 · cited 1×
“Using these techniques, processing parameters such as orientation of jets, material flow rates, and rate of solvent extraction can be controlled to create uniform and well-centered double-walled microspheres exhibiting a controllable shell thickness [52].”
MethodAllison, S. D. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21124 · Cited by 129 · cited 1×
“Additionally, it is possible to tune the overall physical properties of the polymer-drug matrix by controlling the relevant parameters such as polymer molecular weight, ratio of lactide to glycolide and drug concentration to achieve a desired dosage and release interval depending upon the drug type [4–6].”
BackgroundPlasma-treated PET surfaces improve the biocompatibility of human endothelial cells
Ramires, P. A., Mirenghi, L., Romano, A. R., Palumbo, F., & Nicolardi, G. (2000) · Journal of Biomedical Materials Research · doi:10.1002/1097-4636(20000905)51:3 · Cited by 128
Grayson, A. C. R., Cima, M. J., & Langer, R. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.06.033 · Cited by 124
Liggins, R. T., & Burt, H. M. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00690-1 · Cited by 122 · cited 1×
“However this is opposite for PLLA due to an inversely proportional degree of crystallinity with the molecular weight [83,84].”
BackgroundHua, F. J., Park, T. G., & Lee, D. S. (2003) · Polymer · doi:10.1016/s0032-3861(03)00025-9 · Cited by 121
Thomasin, C., Nam‐Trân, H., Merkle, H. P., et al. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970047r · Cited by 113 · cited 1×
“Thus, the coacervation process includes the following three steps as reported in literature [38–40] (1) Phase separation of the coating polymer solution, (2) Adsorption of the coacervate around the drug particles, and (3) Quenching of the microspheres.”
MethodDuvvuri, S., Janoria, K. G., & Mitra, A. K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.002 · Cited by 110
Berchane, N. S., Carson, K. H., Rice-Ficht, A. C., & Andrews, M. J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.12.037 · Cited by 108 · cited 1×
“The equation describing the release is the common diffusion equation: [96]”
BackgroundXu, J. S., Huang, J., Qin, R., Hinkle, G. H., Povoski, S. P., Martin, E. W., & Xu, R. X. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.052 · Cited by 108 · cited 2×
“imaging using fluorescence (FL), ultrasound (US), or photoacoustic tomography (PAT) [69].”
MethodAmann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0152-4 · Cited by 99 · cited 1×
“This has been demonstrated in both in vivo and in vitro for various drug types and proteins with different polymer ratios [72,73].”
BackgroundSelf-citationSynthesis and characterization of elastic PLGA/PCL/PLGA tri-block copolymers
Choi, S. H., & Park, T. G. (2002) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856202320813864 · Cited by 97 · cited 1×
“This motif can also be applied to other co-polymer combinations, including but not limited to various copolymers of PLGA and polycaprolactone [29,30].”
BackgroundPiroxicam release from spray-dried biodegradable microspheres
Wagenaar, B. W., & Müller, B. W. (1994) · Biomaterials · doi:10.1016/0142-9612(94)90196-1 · Cited by 87 · cited 1×
“Various spray drying techniques have been reported [44–49].”
MethodKoushik, K., & Kompella, U. B. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019308.25479.a4 · Cited by 86 · cited 2×
“Using supercritical CO2 as a foaming agent, organic solvents can be minimized or eliminated in production of PLGA foams [66].”
BackgroundEdelman, R., Russell, R. G., Losonsky, G. A., Tall, B. D., Tacket, C. O., Levine, M. M., & Lewis, D. H. (1993) · Vaccine · doi:10.1016/0264-410x(93)90012-m · Cited by 85 · cited 1×
“Thus, the coacervation process includes the following three steps as reported in literature [38–40] (1) Phase separation of the coating polymer solution, (2) Adsorption of the coacervate around the drug particles, and (3) Quenching of the microspheres.”
Method“Programmed polymeric devices” for pulsed drug delivery
Stubbe, B. G., De Smedt, S. C., & Demeester, J. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000045223.45400.01 · Cited by 84 · cited 1×
“Such systems can be extended to achieve programmed delivery of multiple drugs in a predetermined sequence of pulses from a single device [64].”
BackgroundWitt, C. (2001) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(01)00130-8 · Cited by 77 · cited 1×
“It has also been reported that bulk degradation is faster than pure surface degradation for PLGA, which makes the release of the drug faster from the devices with higher surface area to volume [82,86,87].”
BackgroundPreparation and characterization of cephalexin loaded PLGA microspheres
Chaisri, W., Hennink, W., & Okonogi, S. (2009) · Current Drug Delivery · doi:10.2174/156720109787048186 · Cited by 77 · cited 1×
“In double emulsion processes, choice of solvents and stirring rate predominantly affects the encapsulation efficiency and final particle size [32,36,37].”
BackgroundEniola, A. O., & Hammer, D. A. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.03.003 · Cited by 72 · cited 1×
“However, this drug content effect is attenuated when the drug content reaches a certain level depending upon drug type [92].”
BackgroundDong, C., GUO, Y., QIU, K., Gu, Z., & FENG, X. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.05.024 · Cited by 70 · cited 1×
“This motif can also be applied to other co-polymer combinations, including but not limited to various copolymers of PLGA and polycaprolactone [29,30].”
BackgroundNie, H., Lee, L. Y., Tong, H., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.018 · Cited by 70 · cited 1×
“Various spray drying techniques have been reported [44–49].”
MethodThomasin, C., Merkle, H. P., & Gander, B. A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970048j · Cited by 67 · cited 1×
“Thus, the coacervation process includes the following three steps as reported in literature [38–40]”
MethodIn vitro and in vivo demonstration of risperidone implants in mice
Rabin, C., Liang, Y., Ehrlichman, R. S., Budhian, A., Metzger, K. L., Majewski-Tiedeken, C., Winey, K. I., & Siegel, S. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.003 · Cited by 64 · cited 2×
“Solvent-Casting and Compression Molding—Solvent casting is a method to fabricate a macroscopic millimeter size formulation which can be implanted or inserted for long term medication [59].”
BackgroundMethodSelf-citationSastre, R. L., Olmo, R., Teijón, C., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.02.001 · Cited by 57 · cited 1×
“Various spray drying techniques have been reported [44–49].”
MethodPai, S. S., Tilton, R. D., & Przybycien, T. M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9081-8 · Cited by 50 · cited 1×
“Therefore, the remaining gel becomes more hydrophobic in an aqueous environment, resulting in less water content [20,25–28].”
BackgroundSynthesis and Solution Properties of Deferoxamine Amides
Ihnat, P. M., Vennerstrom, J. L., & Robinson, D. H. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200012)89:12 · Cited by 49
PLGA-PEG-PLGA tri-block copolymers as an in-situ gel forming system for calcitonin delivery
Ghahremankhani, A. A., Dorkoosh, F., & Dinarvand, R. (2007) · Polymer Bulletin · doi:10.1007/s00289-007-0807-4 · Cited by 42 · cited 1×
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGAPEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
BackgroundYANG, R., CHEN, T., CHEN, H., & WANG, W. (2005) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2004.07.017 · Cited by 39
Castelli, F., Conti, B., Conte, U., et al. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(95)00195-6 · Cited by 33 · cited 1×
“Various spray drying techniques have been reported [44–49].”
MethodWang, C., Wang, W., Meyer, R. F., Liang, Y., Winey, K. I., & Siegel, S. J. (2010) · Journal of Biomedical Materials Research Part B: Applied Biomaterials · doi:10.1002/jbm.b.31617 · Cited by 33 · cited 1×
“The resulting extrudate is then cooled and solidified before cutting into desired lengths for implants or other applications [61].”
BackgroundSelf-citationMultifunctional microbubbles for image-guided antivascular endothelial growth factor therapy
Zhang, L., Xu, J. S., Sanders, V. E., Letson, A. D., Roberts, C. J., & Xu, R. X. (2010) · Journal of Biomedical Optics · doi:10.1117/1.3457669 · Cited by 16 · cited 1×
“Such multifunctional particles can also be formulated from a component material to reduce side effects of the encapsulated drug [70].”
BackgroundTsuji (2000) · doi:10.1002/1097-4628(20000815)77:7
Jeong (2000) · doi:10.1002/(sici)1097-4636(200005)50:2
Flagged first, then by citations
Cited by
Sorted by citations
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering
Gentile, P., Chiono, V., Carmagnola, I., & Hatton, P. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033640 · Cited by 1,593
“Unlike pure polylactic and polyglycolic acid show poor solubilities, PLGA can be dissolved by a wide range of common solvents, including chlorinated solvents, tetrahydrofuran, acetone or ethyl acetate [28] and it can be processed into any shape and size, and can encapsulate biomolecules of any size.”
BackgroundPlastics of the Future? The Impact of Biodegradable Polymers on the Environment and on Society
Haider, T. P., Völker, C., Kramm, J., Landfester, K., & Wurm, F. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805766 · Cited by 1,658
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,279
Metadata
- Authors
- Makadia, H. K., & Siegel, S. J.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Siegel, Steven J.
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2011-08-26
- Volume
- 3
- Issue
- 3
- Pages
- 1377-1397
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC3347861
- OpenAlex
- W2087032263
- Semantic Scholar
- 3649c008437b4a4a59c67419af5d7fe7bf3594a7
- Cited by
- 4,816
- References
- 98
- Citations by year
- 2026: 490 · 2025: 477 · 2024: 387 · 2023: 394 · 2022: 419 · 2021: 406 · 2020: 435 · 2019: 412 · 2018: 373 · 2017: 305 · 2016: 266 · 2015: 212 · 2014: 138 · 2013: 75 · 2012: 24
- FWCI
- 46.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Mental Health (R01MH074672)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › biodegradable polymer synthesis and properties
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- poly(lactic-co-glycolic acid), PLGA, controlled drug delivery, biodegradable polymers, biocompatibility, drug release, polymer degradation, tissue engineering, small molecule drugs, protein delivery, macromolecule delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review